HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
出版年份 2021 全文链接
标题
HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
作者
关键词
-
出版物
Cancers
Volume 13, Issue 15, Pages 3862
出版商
MDPI AG
发表日期
2021-08-02
DOI
10.3390/cancers13153862
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cholangiocarcinoma 2020: the next horizon in mechanisms and management
- (2020) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- Sirtuins in Metabolic and Epigenetic Regulation of Stem Cells
- (2019) Yi Fang et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo
- (2019) Shilei Liu et al. CANCER SCIENCE
- The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells
- (2019) Kathryn Clarke et al. Oncotarget
- The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer
- (2018) Christian Mayr et al. HUMAN PATHOLOGY
- HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells
- (2018) Joon Wang et al. ONCOLOGY REPORTS
- Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome
- (2017) Eckhard Klieser et al. HUMAN PATHOLOGY
- Histone Deacetylase Inhibitors as Anticancer Drugs
- (2017) Tomas Eckschlager et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition
- (2017) Yuyao Yin et al. Cell Death & Disease
- Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis
- (2017) Mingming Zhang et al. Oncotarget
- Epigenetic Therapeutics: A New Weapon in the War Against Cancer
- (2016) Nita Ahuja et al. Annual Review of Medicine
- Use of class I histone deacetylase inhibitor romidepsin in combination regimens
- (2016) Adam Petrich et al. LEUKEMIA & LYMPHOMA
- HDACs and HDAC Inhibitors in Cancer Development and Therapy
- (2016) Yixuan Li et al. Cold Spring Harbor Perspectives in Medicine
- A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer
- (2016) Takuya Sakamoto et al. PLoS One
- Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines
- (2015) MD. ALI ASGAR et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells
- (2015) Christian Mayr et al. Oncotarget
- The role of polycomb repressive complexes in biliary tract cancer
- (2014) Christian Mayr et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Cholangiocarcinoma
- (2014) Nataliya Razumilava et al. LANCET
- Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin
- (2014) Victoria L. Luchenko et al. Molecular Oncology
- The interplay between microRNAs and histone deacetylases in neurological diseases
- (2014) Megan W. Bourassa et al. NEUROCHEMISTRY INTERNATIONAL
- Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
- (2014) E. Seto et al. Cold Spring Harbor Perspectives in Biology
- Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
- (2013) J. W. Valle et al. ANNALS OF ONCOLOGY
- Histone Deacetylases and their Inhibitors as Potential Therapeutic Drugs for cholangiocarcinoma - Cell Line findings
- (2013) Ruethairat Sriraksa et al. Asian Pacific Journal of Cancer Prevention
- Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells
- (2012) Linda Marek et al. JOURNAL OF MEDICINAL CHEMISTRY
- Histone deacetylases and cancer
- (2012) Bruna Barneda-Zahonero et al. Molecular Oncology
- Overexpression of Histone Deacetylase 2 Predicts Unfavorable Prognosis in Human Gallbladder Carcinoma
- (2012) Xilin Du et al. PATHOLOGY & ONCOLOGY RESEARCH
- Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide
- (2011) J Chang et al. BRITISH JOURNAL OF CANCER
- Romidepsin: a novel histone deacetylase inhibitor for cancer
- (2011) Erin M Bertino et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Role of histone deacetylase expression in intrahepatic cholangiocarcinoma
- (2011) Yuji Morine et al. SURGERY
- Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer
- (2010) Martin Sauvageau et al. Cell Stem Cell
- Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
- (2010) Kyle V. Butler et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Uptake and phototoxicity of meso-tetrahydroxyphenyl chlorine are highly variable in human biliary tract cancer cell lines and correlate with markers of differentiation and proliferation
- (2010) Tobias Kiesslich et al. PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES
- Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma
- (2009) Junpei Yamaguchi et al. CANCER SCIENCE
- MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
- (2008) M. Fournel et al. MOLECULAR CANCER THERAPEUTICS
- Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines
- (2008) Li-Ning Xu et al. WORLD JOURNAL OF GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now